Destiny - Making Positive Changes (Sponsored Research, TP £1.20, 12 pgs)
Last week, Destiny reported positive preclinical safety data for XF-73 Dermal, facilitating its progression to clinical evaluation in diabetic foot ulcer (DFU) & serious burn wound infections. We view XF-73 as bringing a novel approach to treating these serious conditions. The company is exploring partnering options for both the Nasal and Dermal formulations, with this likely to be the next catalyst, in our view. NTCD-M3 also continues to progress, with a change of CDMO and a move to a solid formulation. Destiny is funded through to Q1 2025. For access to our initiation (Aug-2023) and recent note, please contact Naresh Chouhan ( )Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.